• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Complex neuroprotective and neurotoxic effects of histone deacetylases.组蛋白去乙酰化酶的复杂神经保护和神经毒性作用。
J Neurochem. 2018 Apr;145(2):96-110. doi: 10.1111/jnc.14309. Epub 2018 Apr 6.
2
Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.组蛋白去乙酰化酶在神经退行性疾病中的药物干预。
Life Sci. 2020 Feb 15;243:117278. doi: 10.1016/j.lfs.2020.117278. Epub 2020 Jan 8.
3
Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.神经退行性疾病实验模型中的表观遗传组蛋白乙酰化和去乙酰化机制
J Pharmacol Toxicol Methods. 2012 Nov-Dec;66(3):215-20. doi: 10.1016/j.vascn.2012.08.001. Epub 2012 Aug 10.
4
Histone deacetylase inhibitors: possible implications for neurodegenerative disorders.组蛋白去乙酰化酶抑制剂:对神经退行性疾病的潜在影响
Expert Opin Investig Drugs. 2008 Feb;17(2):169-84. doi: 10.1517/13543784.17.2.169.
5
Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases.神经退行性疾病中的表观遗传学:组蛋白去乙酰化酶的作用。
CNS Neurol Disord Drug Targets. 2019;18(1):11-18. doi: 10.2174/1871527317666181004155136.
6
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?HDAC6 作为神经退行性疾病的靶点:它与其他 HDAC 有何不同?
Mol Neurodegener. 2013 Jan 29;8:7. doi: 10.1186/1750-1326-8-7.
7
HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.HDAC6 微管相关蛋白去乙酰化酶:神经退行性疾病潜在的治疗靶点。
J Neurol Sci. 2011 May 15;304(1-2):1-8. doi: 10.1016/j.jns.2011.02.017. Epub 2011 Mar 5.
8
Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise.组蛋白去乙酰化酶抑制剂与神经退行性疾病:带来希望。
Curr Pharm Des. 2009;15(34):3940-57. doi: 10.2174/138161209789649349.
9
Histone deacetylases: focus on the nervous system.组蛋白去乙酰化酶:聚焦于神经系统
Cell Mol Life Sci. 2007 Sep;64(17):2258-69. doi: 10.1007/s00018-007-7035-9.
10
Multiple roles of HDAC inhibition in neurodegenerative conditions.组蛋白去乙酰化酶抑制在神经退行性疾病中的多种作用。
Trends Neurosci. 2009 Nov;32(11):591-601. doi: 10.1016/j.tins.2009.06.002. Epub 2009 Sep 21.

引用本文的文献

1
The Search for Disease Modification in Parkinson's Disease-A Review of the Literature.帕金森病疾病修饰治疗的探索——文献综述
Life (Basel). 2025 Jul 23;15(8):1169. doi: 10.3390/life15081169.
2
Epigenetic Regulation in Ischemic Neuroprotection: The Dual Role of HDACs and HATs in Neuroinflammation and Recovery.缺血性神经保护中的表观遗传调控:组蛋白去乙酰化酶和组蛋白乙酰转移酶在神经炎症和恢复中的双重作用
Antioxidants (Basel). 2025 Aug 19;14(8):1015. doi: 10.3390/antiox14081015.
3
Histone Deacetylase 2 in Alzheimer's Disease: A Comprehensive Molecular Blueprint for Therapeutic Targeting.阿尔茨海默病中的组蛋白去乙酰化酶2:治疗靶点的全面分子蓝图
Mol Neurobiol. 2025 Aug 8. doi: 10.1007/s12035-025-05264-y.
4
Sulforaphane and Brain Health: From Pathways of Action to Effects on Specific Disorders.萝卜硫素与脑健康:从作用途径到对特定疾病的影响
Nutrients. 2025 Apr 15;17(8):1353. doi: 10.3390/nu17081353.
5
HDAC3 as an Emerging Therapeutic Target for Alzheimer's Disease and other Neurological Disorders.组蛋白去乙酰化酶3作为阿尔茨海默病和其他神经疾病的新兴治疗靶点。
Mol Neurobiol. 2025 Mar 24. doi: 10.1007/s12035-025-04866-w.
6
Contilisant-Belinostat Hybrids: Polyfunctionalized Indole Derivatives as Multineurotarget Drugs for the Potential Treatment of Alzheimer's Disease.Contilisant-贝利司他杂合物:作为潜在治疗阿尔茨海默病的多神经靶点药物的多官能化吲哚衍生物
ACS Pharmacol Transl Sci. 2025 Feb 7;8(3):831-840. doi: 10.1021/acsptsci.4c00709. eCollection 2025 Mar 14.
7
Exploring Histone Modifications in Inherited Retinal Disorders.探索遗传性视网膜疾病中的组蛋白修饰
Adv Exp Med Biol. 2025;1468:189-193. doi: 10.1007/978-3-031-76550-6_31.
8
Histone Deacetylation in Alzheimer's Diseases (AD); Hope or Hype.阿尔茨海默病(AD)中的组蛋白去乙酰化:希望还是炒作?
Cell Biochem Biophys. 2025 Jun;83(2):1537-1553. doi: 10.1007/s12013-025-01670-0. Epub 2025 Jan 18.
9
Role of histone deacetylase inhibitors in non-neoplastic diseases.组蛋白去乙酰化酶抑制剂在非肿瘤性疾病中的作用。
Heliyon. 2024 Jul 2;10(13):e33997. doi: 10.1016/j.heliyon.2024.e33997. eCollection 2024 Jul 15.
10
Molecular Mechanisms of Medicinal Plant -derived Compound Securinine against Spinal Muscular Atrophy based on Network Pharmacology and Experimental Verification.基于网络药理学和实验验证的药用植物衍生化合物血根碱治疗脊髓性肌萎缩症的分子机制。
Curr Pharm Des. 2024;30(15):1178-1193. doi: 10.2174/0113816128288504240321041408.

本文引用的文献

1
Recent advances in the discovery of potent and selective HDAC6 inhibitors.强效和选择性HDAC6抑制剂发现方面的最新进展。
Eur J Med Chem. 2018 Jan 1;143:1406-1418. doi: 10.1016/j.ejmech.2017.10.040. Epub 2017 Oct 16.
2
A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.组蛋白去乙酰化酶 3 的选择性抑制剂可预防亨廷顿病小鼠的认知缺陷,并抑制纹状体 CAG 重复扩展。
Sci Rep. 2017 Jul 20;7(1):6082. doi: 10.1038/s41598-017-05125-2.
3
Subcellular Distribution of HDAC1 in Neurotoxic Conditions Is Dependent on Serine Phosphorylation.神经毒性条件下HDAC1的亚细胞分布依赖于丝氨酸磷酸化。
J Neurosci. 2017 Aug 2;37(31):7547-7559. doi: 10.1523/JNEUROSCI.3000-16.2017. Epub 2017 Jun 29.
4
Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.挽救异常的组蛋白去乙酰化酶活性可恢复 Angelman 综合征小鼠模型的行为异常。
Neurobiol Dis. 2017 Sep;105:99-108. doi: 10.1016/j.nbd.2017.05.010. Epub 2017 May 30.
5
Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.Foxp1表达降低作为亨廷顿舞蹈病的一个促成因素
J Neurosci. 2017 Jul 5;37(27):6575-6587. doi: 10.1523/JNEUROSCI.3612-16.2017. Epub 2017 May 26.
6
Targeting Class I Histone Deacetylases in a "Complex" Environment.靶向“复杂”环境中的 I 类组蛋白去乙酰化酶。
Trends Pharmacol Sci. 2017 Apr;38(4):363-377. doi: 10.1016/j.tips.2016.12.006. Epub 2017 Jan 28.
7
Inhibition of Histone Deacetylase 3 (HDAC3) Mediates Ischemic Preconditioning and Protects Cortical Neurons against Ischemia in Rats.组蛋白去乙酰化酶3(HDAC3)的抑制介导缺血预处理并保护大鼠皮质神经元免受缺血损伤。
Front Mol Neurosci. 2016 Nov 28;9:131. doi: 10.3389/fnmol.2016.00131. eCollection 2016.
8
Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.开发改良的HDAC6抑制剂作为轴索性夏科-马里-图斯病的药物治疗方法。
Neurotherapeutics. 2017 Apr;14(2):417-428. doi: 10.1007/s13311-016-0501-z.
9
Therapeutic role of sirtuins in neurodegenerative disease and their modulation by polyphenols.Sirtuins 在神经退行性疾病中的治疗作用及其被多酚的调节。
Neurosci Biobehav Rev. 2017 Feb;73:39-47. doi: 10.1016/j.neubiorev.2016.11.022. Epub 2016 Nov 30.
10
Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders.沉默调节蛋白及其在脑衰老和神经退行性疾病中的作用。
Neurochem Res. 2017 Mar;42(3):876-890. doi: 10.1007/s11064-016-2110-y. Epub 2016 Nov 24.

组蛋白去乙酰化酶的复杂神经保护和神经毒性作用。

Complex neuroprotective and neurotoxic effects of histone deacetylases.

机构信息

Department of Neuroscience, The Scripps Research Institute, La Jolla, California, USA.

Department of Biological Sciences, Southern Methodist University, Dallas, Texas, USA.

出版信息

J Neurochem. 2018 Apr;145(2):96-110. doi: 10.1111/jnc.14309. Epub 2018 Apr 6.

DOI:10.1111/jnc.14309
PMID:29355955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5920706/
Abstract

By their ability to shatter quality of life for both patients and caregivers, neurodegenerative diseases are the most devastating of human disorders. Unfortunately, there are no effective or long-terms treatments capable of slowing down the relentless loss of neurons in any of these diseases. One impediment is the lack of detailed knowledge of the molecular mechanisms underlying the processes of neurodegeneration. While some neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, are mostly sporadic in nature, driven by both environment and genetic susceptibility, many others, including Huntington's disease, spinocerebellar ataxias, and spinal-bulbar muscular atrophy, are genetically inherited disorders. Surprisingly, given their different roots and etiologies, both sporadic and genetic neurodegenerative disorders have been linked to disease mechanisms involving histone deacetylase (HDAC) proteins, which consists of 18 family members with diverse functions. While most studies have implicated certain HDAC subtypes in promoting neurodegeneration, a substantial body of literature suggests that other HDAC proteins can preserve neuronal viability. Of particular interest, however, is the recent realization that a single HDAC subtype can have both neuroprotective and neurotoxic effects. Diverse mechanisms, beyond transcriptional regulation have been linked to these effects, including deacetylation of non-histone proteins, protein-protein interactions, post-translational modifications of the HDAC proteins themselves and direct interactions with disease proteins. The roles of these HDACs in both sporadic and genetic neurodegenerative diseases will be discussed in the current review.

摘要

神经退行性疾病通过破坏患者和护理人员的生活质量,成为了最具破坏性的人类疾病。不幸的是,目前尚无有效的长期治疗方法能够减缓这些疾病中神经元的持续丧失。其中一个障碍是缺乏对神经退行性过程中分子机制的详细了解。虽然某些神经退行性疾病,如阿尔茨海默病、帕金森病和肌萎缩侧索硬化症,在很大程度上是散发性的,由环境和遗传易感性共同驱动,但许多其他疾病,包括亨廷顿病、脊髓小脑共济失调和脊髓延髓肌肉萎缩症,都是遗传性疾病。令人惊讶的是,尽管它们的根源和病因不同,散发性和遗传性神经退行性疾病都与涉及组蛋白去乙酰化酶(HDAC)蛋白的疾病机制有关,这些蛋白由具有不同功能的 18 个家族成员组成。虽然大多数研究都表明某些 HDAC 亚型在促进神经退行性变中起作用,但大量文献表明,其他 HDAC 蛋白可以维持神经元的存活。然而,特别引人关注的是,最近人们意识到单个 HDAC 亚型可以同时具有神经保护和神经毒性作用。除了转录调节之外,还与这些作用相关的有多种机制,包括非组蛋白蛋白的去乙酰化、蛋白-蛋白相互作用、HDAC 蛋白本身的翻译后修饰以及与疾病蛋白的直接相互作用。本文将讨论这些 HDAC 在散发性和遗传性神经退行性疾病中的作用。